Nafazair / naphazoline hydrochloride NDA 088101 global drug patent coverage, generic alternatives and manufacturers

Generated: August 22, 2017

NDA 088101 describes NAFAZAIR, which is a drug marketed by Pharmafair and Bausch And Lomb and is included in two NDAs. Additional details are available on the NAFAZAIR profile page.

The generic ingredient in NAFAZAIR is naphazoline hydrochloride. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the naphazoline hydrochloride profile page.

Summary for NDA: 088101

Tradename:	1
Applicant:	1
Ingredient:	1
Patents:	0
Therapeutic Class:	Ophthalmic Agents
Formulation / Manufacturing:	see details

Summary for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	SOLUTION/DROPS;OPHTHALMIC			Strength	0.1%
Approval Date:	Apr 15, 1983	TE:		RLD:	No

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.